Company intelligence / Profile preview
Jecho Biopharmaceuticals Co., Ltd.
Sino-Singapore Tianjin Eco-city, Tianjin, Chinajechobio.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Phase 1
01
Overview
The company has multiple drug candidates at various clinical stages, with the most advanced being a Ranibizumab biosimilar for wet age-related macular degeneration in Phase 3 trials
- Therapeutic areas
- OncologyImmunologyOphthalmologyNephrologyInfectious Diseases
- Modalities
- Monoclonal antibodiesRecombinant proteinsOncolytic virusesImmunotoxinsVaccinesFusion proteinsBispecific antibodiesBispecific T-cell Engagers (BiTE)Oncolytic bacteriaFab fragmentsCytokines
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Beyond the preview
Go deeper on Jecho Biopharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jecho Biopharmaceuticals Co., Ltd..